Exchange: NASDAQ·Updated 07:04 PM EDT
BVS logo

BVSBioventus Inc - Ordinary Shares - Class A

$9.44
$0.34
(3.48%)
Today
Closed $9.44
$0.15
(1.59%)
After Hours
EarningsAug 4
Mkt Cap$816.97M
Vol728,969.00
News
all
press releases
Should Value Investors Buy Bioventus (BVS) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks
News Placeholder
More News
News Placeholder
Are Medical Stocks Lagging BrightSpring Health Services, Inc. (BTSG) This Year?
Here is how BrightSpring Health Services, Inc. (BTSG) and Bioventus (BVS) have performed compared to their sector so far this year.
Zacks
News Placeholder
Are Investors Undervaluing Bioventus (BVS) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks
News Placeholder
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?
Here is how Allarity Therapeutics, Inc. (ALLR) and Bioventus (BVS) have performed compared to their sector so far this year.
Zacks
News Placeholder
After Plunging 22% in 4 Weeks, Here's Why the Trend Might Reverse for Bioventus (BVS)
The heavy selling pressure might have exhausted for Bioventus (BVS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks
News Placeholder
The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts
The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts PR Newswire TAMPA, Fla., June 2, 2026 Issued on behalf of Conexeu Sciences Inc.A newly listed...
PR Newswire
News Placeholder
Transcript: Bioventus Q1 2026 Earnings Conference Call
read more...
Benzinga
News Placeholder
Bioventus (BVS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Bioventus (BVS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Zacks
News Placeholder
Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It
Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It PR Newswire NEW YORK, May 22, 2026 Issued on behalf of Conexeu Sciences Inc.Companies mentioned: Conexeu Sciences Inc. (NASDAQ...
PR Newswire
News Placeholder
Is Bioventus (BVS) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks
<
1
2
...
>

Advertisement|Remove ads.